Motion tracking during lung cancer radiotherapy using real-time MRI
Official title: Combining 4D MRI and 4DCT for Personalized Volumetric Motion Monitoring in Lung Radiation Therapy
Run by University of Maryland, Baltimore · NCT07398209 · Data updated 2026-11-12
A trial tests real-time tracking of lung tumor motion during radiation therapy in adults with certain stages of NSCLC to see if MRI can help guide treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 44 (estimated) |
| Sponsor | University of Maryland, Baltimore Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy, radiation |
| Locations | 1 site (Baltimore, Maryland) |
| Status | Recruiting |
| Started | April 14, 2026 |
| Main results expected | April 2028 |
| Study ends | April 2029 |
| Registry record updated | June 26, 2026 |
| Trial ID | NCT07398209 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with histologically confirmed stage II–IIIb NSCLC undergoing definitive external beam radiotherapy and able to have MRI.
✕Probably not a fit
Patients unable to undergo MRI or without the ability to benefit from motion-guided targeting may not receive additional benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study uses four-dimensional MRI to track lung tumor motion and nearby organs during external beam radiotherapy. During treatment, X-ray fluoroscopy images are also used to correlate motion with delivery. The goal is to understand whether real-time motion information can improve precision of radiation targeting. Eligible participants have stage II-IIIb NSCLC and are receiving definitive radiotherapy, with MRI compatible and able to undergo MRI scans. The sponsor is the University of Maryland, with the University of Maryland Greenebaum Cancer Center as the site.
Why it matters
Potential benefit: If successful, real-time motion tracking could improve targeting accuracy and potentially reduce side effects by sparing healthy tissue.
How similar studies have gone: Prior studies in motion management have shown promise in other sites, but this exact MRI-based real-time approach in NSCLC is being explored.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adult (≥18 years) patients (both sexes) with histologically diagnosed Stage II-IIIb NSCLC 2. Patients to be treated with definitive external beam photon radiotherapy with or without systemic therapy (e.g., chemotherapy, immunotherapy). 3. No restrictions on number radiotherapy fractions, or location/number of lesions 4. ECOG performance status ≤ 3 5. Ability to undergo MRI scans 6. Patient has signed informed consent document and agreed to study procedures Exclusion Criteria: 1. Pre-existing contraindications for MRI, such as any MRI-conditional or MRI-unsafe foreign objects within the body, non-removable ear cochlear or eye implant, aneurysm clip, cardiac pacemaker/wires, internal defibrillator, tissue expander, recent stent placement, penile prosthesis, medication patch, artificial limb, pregnancy, and claustrophobia 2. Women who are pregnant or trying to get pregnant (self-reported) 3. Pain in supine position or inability to raise arm above head in supine position
Where it's running
-
University of Maryland Greenebaum Cancer Center
Baltimore, Maryland, United States Recruiting
Study contacts
- Principal investigator: Amit Sawant, PhD — University of Maryland, Baltimore
- Study coordinator: Amit Sawant, PhD
- Email: asawant@som.umaryland.edu
- Phone: 410-328-6080
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Understanding what patients want from NSCLC treatment monitoring
Researchers are testing how patients with non-small cell lung cancer feel about and prefer monitoring their symptoms during treatment, with input from patients, caregivers, and clinicians.
-
PD-L1-targeted PET probe to map PD-L1 in solid tumors
A PET tracer called 18F-F-PDL1-3 is being tested to see if it can detect PD-L1 expression in primary and metastatic tumors to help guide personalized treatment.
-
Cardiorespiratory fitness after lobectomy versus sublobar resection in NSCLC
This study tests how different lung surgeries (lobectomy vs. sublobar resection) affect fitness levels after surgery in people with non-small cell lung cancer.
-
CAIX-targeted PET/CT imaging in solid tumors
Researchers are testing a CAIX-targeted PET/CT imaging agent to see if it detects and reflects CAIX levels in solid tumors like clear cell renal cell carcinoma, NSCLC, and breast cancer.
-
NUT Project: Nutritional Support in Thoracic Cancer
We’ll see if providing tailored nutrition guidance and assessment helps people with advanced lung cancer during their treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.